NAVAL DAVER to Phenylurea Compounds
This is a "connection" page, showing publications NAVAL DAVER has written about Phenylurea Compounds.
Connection Strength
0.885
-
Sorafenib and novel multikinase inhibitors in AML. Lancet Oncol. 2015 Dec; 16(16):1582-3.
Score: 0.401
-
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.
Score: 0.181
-
New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020 10 30; 10(10):107.
Score: 0.142
-
Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
Score: 0.078
-
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
Score: 0.037
-
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70.
Score: 0.025
-
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
Score: 0.021